Markets

Trinity Biotech (TRIB) Falls: Stock Goes Down 5.4% - Tale of the Tape

Trinity Biotech plc ( TRIB ) saw a big move last session, as the company's shares fell by over 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $25.61 to $27.81 in the past one-month time frame.

This slump shouldn't be too much of a surprise to investors, as the company has seen 1 negative revisions in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.

TRIB currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the same sector include Siemens Baxter Inernational Inc. ( BAX ), Covidien plc ( COV ) and Meridian Bioscience, Inc. ( VIVO ). All these stocks hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

BAXTER INTL (BAX): Free Stock Analysis Report

COVIDIEN PLC (COV): Free Stock Analysis Report

TRINITY BIOTECH (TRIB): Free Stock Analysis Report

MERIDIAN BIOSCI (VIVO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TRIB BAX VIVO

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More